The biological targeted agent tildrakizumab specifically antagonizes IL-23 and targets the p19 subunit of IL-23 to inhibit inflammation; it has been used in the clinical treatment of psoriasis while regulating the tumor microenvironment and has been in phase I/II clinical studies for the treatment of prostate cancer [64,65]. The gene discussed is IL23A; the disease is prostate cancer.